Baricitinib and Fedratinib, which show selectivity for JAK2 over JAK3, have gained approval for myelofibrosis while Upadacitinib, which has selectivity for JAK1, has obtained approval for the treatment of rheumatoid arthritis. This evidence concerns the gene JAK3 and myelofibrosis.